Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare Biotechnology

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc

Bullboard Posts

Post by Benedict16thon Nov 16, 2020 4:58pm

787 Views

Post# 31911034

Buffet VS GUD

Warren Buffett’s Berkshire Hathaway made a slew of big changes to its equity portfolio in the third quarter, including building new sizeable stakes in a few pharmaceutical stocks and dramatically cutting its longtime JPMorgan Chase investment.

The conglomerate bought 21.3 million shares of Abbvie, 22.4 millions of Merck, 3.7 million shares of Pfizer and 29.97 million shares in Bristol-Myers Squibb in the third quarter, according to a new 13F filing. Berkshire also picked up 2.4 million shares of T-Mobile last quarter.

Bullboard Posts

Global Tungsten Market and Supply Security